百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06160 百济神州

未开盘 05-07 16:08:25

141.000

-12.200

-7.96%

最高149.300	最低141.000	成交量1,049万
今开148.300	昨收153.200	日振幅5.42%
总市值1,978亿	流通市值1,816亿	总股本14.03亿
成交额15.06亿	换手率0.81%	流通股本12.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":141,"timestamp":1746605305021,"preClose":153.2,"halted":0,"volume":10493026,"delay":0,"floatShares":1288000000,"shares":1403000000,"eps":-3.6554795955582797,"marketStatus":"未开盘","change":-12.2,"latestTime":"05-07 16:08:25","open":148.3,"high":149.3,"low":141,"amount":1505851747,"amplitude":0.054178,"askPrice":141.1,"askSize":22000,"bidPrice":141,"bidSize":21700,"shortable":3,"etf":0,"ttmEps":-3.6554795955582797,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746667800000},"marketStatusCode":0,"adr":0,"listingDate":1533657600000,"exchange":"SEHK","adjPreClose":153.2,"openAndCloseTimeList":[[1746581400000,1746590400000],[1746594000000,1746604800000]],"volumeRatio":2.178862,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":238.5,"timestamp":1746601200000,"preClose":259,"halted":0,"volume":4089300,"delay":0,"premium":"-44.98"}},"requestUrl":"/m/hq/s/06160","defaultTab":"news","newsList":[{"id":"2533932462","title":"百济神州一季度亏损大幅收窄 国内BTK抑制剂销售加速、PD-1销售减速","url":"https://stock-news.laohu8.com/highlight/detail?id=2533932462","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533932462?lang=zh_cn&edition=full","pubTime":"2025-05-07 22:41","pubTimestamp":1746628873,"startTime":"0","endTime":"0","summary":"作为国内创新药龙头企业，百济神州目前有3款主要自研产品，分别为BTK抑制剂泽布替尼、PD-1单抗替雷利珠单抗和PARP抑制剂帕米帕利。对于一季度的产品收入增长，公司归因于百悦泽、百泽安及安进授权产品的销售增长。具体来说，今年第一季度，百悦泽全球销售额总计56.92亿元，同比增长63.7%。而在竞争更为激烈的国内PD-1单抗市场中，百泽安实现销售额12.45亿元，同比增长19.3%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050722420597521340&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050722420597521340&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1169589451.USD","BK4139","ONC","BK4023","688235","LU1169590202.USD","PD","06160"],"gpt_icon":0},{"id":"2533939776","title":"百济神州一季度产品收入近80亿元：跨越“创新鸿沟”，全球化突围成盈利胜负手","url":"https://stock-news.laohu8.com/highlight/detail?id=2533939776","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533939776?lang=zh_cn&edition=full","pubTime":"2025-05-07 21:53","pubTimestamp":1746625980,"startTime":"0","endTime":"0","summary":"具体来看，业绩快报显示，百济神州实现营收80.48亿元，同比增长50.2%。基于此，百济神州预计2025年全年营业收入将介于人民币 352亿元至 381 亿元之间。目前，泽布替尼在全球75个市场获批，同时本季度在11个市场新增纳入或扩大报销范围。目前，该产品已在全球46个市场获批上市，超150万例患者接受治疗。在海外市场，百济神州在2024年10月初高调宣布，其PD-1抗癌药物替雷利珠单抗在获得FDA批准六个多月后，终于在美国正式上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507215548a4757443&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507215548a4757443&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","688235","06160"],"gpt_icon":0},{"id":"2533936482","title":"年内股价涨幅超三成的百济神州，一季度营业利润扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2533936482","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533936482?lang=zh_cn&edition=full","pubTime":"2025-05-07 21:40","pubTimestamp":1746625243,"startTime":"0","endTime":"0","summary":"今年以来，百济神州（ONC.NS、06160.HK、688235.SH）美股、港股、A股三地的股价累计涨幅均超过30%。5月7日晚间，百济神州公布的2025年第一季度美股业绩报告及A股业绩快报显示，公司业绩有继续向好趋势。百济神州A股业绩快报显示，2025年第一季度，公司实现营业利润、利润总额由亏损转为盈利，均实现盈利1.5亿元左右。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505073398404544.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505073398404544.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","LU0588546209.SGD","BK1161","ONC","BK1583","BK1500","BK1588","BK4139","LU0307460666.USD","LU2328871848.SGD","06160"],"gpt_icon":0},{"id":"2533933848","title":"百济神州一季度总收入同比增49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533933848","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533933848?lang=zh_cn&edition=full","pubTime":"2025-05-07 20:55","pubTimestamp":1746622503,"startTime":"0","endTime":"0","summary":"5月7日，百济神州发布公告，公布其截至2025年3月31日止的第一季度未经审计财务业绩。报告显示，第一季度总收入达到11亿美元，同比增长49%。在费用方面，第一季度的研发费用为4.82亿美元，销售及管理费用为4.59亿美元，合计经营费用为9.41亿美元，同比增长6%。GAAP净利润为127万美元，而上年同期为亏损2.51亿美元。2024年，百济神州实现收入272.14亿元，归母净利润-49.78亿元。文章来源：财中社百济神州一季度总收入同比增49% GAAP净利润127万美元","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507210701a47568a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507210701a47568a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","LU0588546209.SGD","BK1161","BK1583","BK1500","BK1588","LU0307460666.USD","LU2328871848.SGD","06160"],"gpt_icon":0},{"id":"2533809959","title":"百济神州第一季度净利亏损9450.3万元，同比大幅减亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2533809959","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533809959?lang=zh_cn&edition=full","pubTime":"2025-05-07 20:33","pubTimestamp":1746621226,"startTime":"0","endTime":"0","summary":"北京商报讯（记者丁宁）5月7日晚间，百济神州（688235）发布2025年第一季度主要财务数据公告显示，报告期内，公司实现营业收入80.48亿元，同比增长50.2%；归属净利润为-9450.3万元，上年同期为-19.08亿元，同比大幅减亏。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505073398350324.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505073398350324.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ONC","LU2328871848.SGD","BK1161","LU0588546209.SGD","LU0307460666.USD","BK1583","06160","BK1500","BK1588","LU1969619763.USD","BK4139"],"gpt_icon":0},{"id":"2533984281","title":"百济神州(688235.SH)一季度营业总收入80.48亿元，同比增长50.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533984281","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533984281?lang=zh_cn&edition=full","pubTime":"2025-05-07 20:02","pubTimestamp":1746619377,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(688235.SH)布2025年第一季度主要财务数据公告，报告期内，公司实现营业总收入80.48亿元，同比增长50.2%:其中产品收入79.85亿元，同比增长49.9%。营业利润、利润总额由亏损转为盈利。产品收入的增长主要得益于公司自研产品百悦泽®(泽布替尼胶囊),以及百泽安®(替雷利珠单抗)和安进授权产品的销售增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290421.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ONC","LU2328871848.SGD","BK1161","688235","LU0588546209.SGD","LU0307460666.USD","BK1583","06160","BK1500","BK1588","LU1969619763.USD","BK4139","BK0239"],"gpt_icon":0},{"id":"2533264981","title":"百济神州（06160）2025Q1强劲增长 首次实现季度GAAP盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2533264981","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533264981?lang=zh_cn&edition=full","pubTime":"2025-05-07 19:43","pubTimestamp":1746618233,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2025年5月7日，百济神州发布2025年第一季度美股业绩报告及A股业绩快报。业绩快报显示，百济神州实现营收80.48亿元，同比增长50.2%。财务表现方面，2025年第一季度，百济神州凭借全球收入的快速增长和经营费用的有效管理，在盈利方面再次取得重大进展。目前，该产品已在全球46个市场获批上市，超150万例患者接受治疗。同时，百济神州预计将于2025年下半年完成BGB-58067和BG-89894联合治疗临床试验的首例患者入组。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290401.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK0239","LU1969619763.USD","LU0588546209.SGD","BK1161","BK1500","688235","BK1588","LU2328871848.SGD","06160","BK1583","LU0307460666.USD","ONC"],"gpt_icon":0},{"id":"2533848699","title":"A股公告精选 | 百济神州(688235.SH)第一季度营业利润、利润总额由亏转盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2533848699","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533848699?lang=zh_cn&edition=full","pubTime":"2025-05-07 19:39","pubTimestamp":1746617962,"startTime":"0","endTime":"0","summary":"今日关注百济神州、源杰科技、纬德信息等公司公告。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20250507/20250507193933_19933.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20250507/20250507193933_19933.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1969619763.USD","BK1161","688235","ONC","399300","BK4139","LU2328871848.SGD","06160","BK1583","LU0307460666.USD","LU0588546209.SGD","159982","BK1500","BK1588","BK0239"],"gpt_icon":0},{"id":"2533098132","title":"百济神州：第一季度净亏损9450.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533098132","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533098132?lang=zh_cn&edition=full","pubTime":"2025-05-07 19:23","pubTimestamp":1746616993,"startTime":"0","endTime":"0","summary":"每经AI快讯，百济神州5月7日发布2025年第一季度主要财务数据公告，报告期内，公司实现营业总收入80.48亿元，同比增长50.2%；归属于母公司所有者的净利润为-9450.3万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505073398303029.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505073398303029.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0588546209.SGD","LU1969619763.USD","06160","BK1500","BK4139","ONC","LU0307460666.USD","BK1161","BK1583","LU2328871848.SGD","BK1588"],"gpt_icon":0},{"id":"2533983707","title":"百济神州Q1营收增长50.2%至80.48亿元，百悦泽®全球销售额总计56.92亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2533983707","media":"财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533983707?lang=zh_cn&edition=full","pubTime":"2025-05-07 19:05","pubTimestamp":1746615944,"startTime":"0","endTime":"0","summary":"5月7日，百济神州发布2025年一季报。披露公司Q1营收增长50.2%至80.48亿元，净亏损9450.3万元。2025年第一季度，百悦泽全球销售额总计56.92亿元，同比增长63.7%，在血液肿瘤领域进一步巩固领导地位。中国销售额总计5.90亿元，同比增长43.1%，主要得益于该产品在已获批适应症领域的销售增长。百悦泽临床开发项目迄今已在全球超过30个国家和地区开展超过35项试验，入组约7,100例患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050719061994ef2bc1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050719061994ef2bc1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","06160","688235"],"gpt_icon":0},{"id":"2533865329","title":"百济神州、宜联新药IND！礼来重金加注、AZ联合疗法新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2533865329","media":"医药经济报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533865329?lang=zh_cn&edition=full","pubTime":"2025-05-07 19:02","pubTimestamp":1746615770,"startTime":"0","endTime":"0","summary":"百济神州1类新药获批临床日前，CDE官网公示，百济神州申报的1类新药BGB-45035片就新适应症获得临床试验默示许可，拟开发治疗结节性痒疹。本次BGB-45035针对结节性痒疹新适应症获批临床，意味着该产品的临床开发迎来新的进展。此前，Alchemab宣布与礼来达成协议。值得一提的是，根据ECHO的结果，阿可替尼联合苯达莫司汀和利妥昔单抗疗法已于2025年1月17日获FDA批准用于MCL一线治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507191622a475488d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507191622a475488d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0106261372.USD","LU0122379950.USD","SG9999014880.SGD","LU2750360641.GBP","LU0820561818.USD","688235","LLY","AZ","LU2602419157.SGD","LU1868836591.USD","LU2237443978.SGD","LU0289739699.SGD","BK4187","BK4533","LU0471298777.SGD","LU1093756168.USD","LU2211815571.USD","IE0004445239.USD","LU1267930730.SGD","LU2361044865.SGD","LU2491050071.SGD","LU2471134952.CNY","LU1720051108.HKD","SG9999001176.USD","SG9999014906.USD","LU0198837287.USD","LU1093756325.SGD","SG9999015978.USD","LU2552382215.SGD","IE00BK4W5L77.USD","LU0203201768.USD","IE00B2B36J28.USD","LU0882574139.USD","LU2237438978.USD","LU0266013472.USD","ONC","SG9999014914.USD","IE00B1BXHZ80.USD","LU2237443382.USD","LU1720051017.SGD","LU1917777945.USD","LU2264538146.SGD","SG9999001176.SGD","SGXZ99366536.SGD","06160","LU0640476718.USD","GB00BDT5M118.USD","LU0354030438.USD","LU2112291526.USD","IE00BFTCPJ56.SGD","LU2237443549.SGD","LU2491050154.USD"],"gpt_icon":1},{"id":"2533998339","title":"【百济神州：2025年第一季度净亏损9450.3万元】百济神州公告，2025年第一季度实现营业总收入80.48亿元，同比增长50.2%；产品收入79.85亿元，同比增长49.9%；营业利润1.51亿元，去年同期为亏损18.3亿元；归属于母公司所有者的净利润亏损9450.3万元，去年同期亏损19.08亿元；产品收入增长主要得益于自研产品百悦泽®和百泽安®的销售增长。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533998339","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533998339?lang=zh_cn&edition=full","pubTime":"2025-05-07 18:57","pubTimestamp":1746615437,"startTime":"0","endTime":"0","summary":"百济神州公告，2025年第一季度实现营业总收入80.48亿元，同比增长50.2%；产品收入79.85亿元，同比增长49.9%；营业利润1.51亿元，去年同期为亏损18.3亿元；归属于母公司所有者的净利润亏损9450.3万元，去年同期亏损19.08亿元；产品收入增长主要得益于自研产品百悦泽®和百泽安®的销售增长。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/07185750201368.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ONC","688235","06160"],"gpt_icon":0},{"id":"2533988218","title":"百济神州：2025年第一季度净亏损9450.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533988218","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533988218?lang=zh_cn&edition=full","pubTime":"2025-05-07 18:57","pubTimestamp":1746615436,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1500","ONC","688235","BK1583","LU2328871848.SGD","BK1161","LU1969619763.USD","LU0588546209.SGD","BK4139","BK1588","BK0239","LU0307460666.USD","06160"],"gpt_icon":0},{"id":"2533076976","title":"百济神州第一季度经调整净利润1.36亿美元 首次跃居BTK抑制剂市场的整体份额首位","url":"https://stock-news.laohu8.com/highlight/detail?id=2533076976","media":"格隆汇","labels":["viewpoints"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533076976?lang=zh_cn&edition=full","pubTime":"2025-05-07 18:17","pubTimestamp":1746613052,"startTime":"0","endTime":"0","summary":"期间GAAP净利润127万美元，上年同期亏损2.51亿美元；经调整净利润1.36亿美元，上年同期亏损1.46亿美元。“本季度，公司再创卓越业绩，首次实现GAAP季度盈利，全球收入持续增长。在美国，百悦泽在慢性淋巴细胞白血病各线治疗中新发患者使用率继续领跑，并首次跃居BTK抑制剂市场的整体份额首位”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507181732a475360d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507181732a475360d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"百济神州第一季度经调整净利润1.36亿美元 首次跃居BTK抑制剂市场的整体份额首位","news_tag":"viewpoints","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160"],"gpt_icon":1},{"id":"2533904604","title":"百济神州(06160)第一季度总收入11.17亿美元 同比增加49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533904604","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533904604?lang=zh_cn&edition=full","pubTime":"2025-05-07 18:10","pubTimestamp":1746612621,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州 发布2025年第一季度业绩，该集团取得总收入11.17亿美元，同比增加49%;GAAP净利润127万美元，去年同期则亏损2.51亿美元;经调整净利润1.36亿美元，去年同期则取得亏损1.46亿美元; GAAP基本每股美国存托股份收益0.01美元。公告称，总收入的增长主要得益于百悦泽在美国和欧洲的销售额增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290295.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1969619763.USD","LU0588546209.SGD","BK1161","ONC","BK0239","BK1583","BK1500","688235","BK1588","BK4139","LU0307460666.USD","LU2328871848.SGD","06160"],"gpt_icon":0},{"id":"2533604503","title":"百济神州05月07日主力净流出6761.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2533604503","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533604503?lang=zh_cn&edition=full","pubTime":"2025-05-07 16:15","pubTimestamp":1746605745,"startTime":"0","endTime":"0","summary":"05月07日, 百济神州股价跌7.96%，报收141.00元，成交金额15.1亿元，换手率0.81%，振幅5.42%，量比2.17。百济神州今日主力资金净流出6761.9万元，上一交易日主力净流入539.8万元。该股近5个交易日下跌1.50%，主力资金累计净流出1491.3万元；近20日主力资金累计净流入3.0亿元，其中净流入天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507171559a475238f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507171559a475238f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1500","LU0307460666.USD","LU2328871848.SGD","06160","LU0588546209.SGD","LU1969619763.USD","BK1588","BK1583"],"gpt_icon":0},{"id":"2533673292","title":"【香港恒生指数收涨0.13% 恒生科技指数跌0.75%】香港恒生指数收涨0.13%，恒生科技指数跌0.75%。博雷顿上市首日涨超38%，弘业期货涨超34%；百济神州跌超7%，药明生物跌超6%，泡泡玛特跌超5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533673292","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533673292?lang=zh_cn&edition=full","pubTime":"2025-05-07 16:10","pubTimestamp":1746605453,"startTime":"0","endTime":"0","summary":"香港恒生指数收涨0.13%，恒生科技指数跌0.75%。博雷顿上市首日涨超38%，弘业期货涨超34%；百济神州跌超7%，药明生物跌超6%，泡泡玛特跌超5%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/07161050191141.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0140636845.USD","HHImain","LU0417516902.SGD","06160","BK1147","BK1589","BK1592","09992","BK1161","LU0979878070.USD","513600","LU2039709279.SGD","BK1175","03678","BK1564","LU0823426480.USD","LU0572944931.SGD","LU0348825331.USD","LU1969619763.USD","BK1576","BK1583","LU0819121731.USD","LU0359202008.SGD","LU0516422440.USD","02269","02833","HSTECH","LU1242518857.USD","LU1242518931.SGD","LU1880383366.USD","LU0307460666.USD","MCHmain","LU0456827905.SGD","LU0348735423.USD","001236","LU0359201612.USD","HSI","LU0417516738.SGD","LU0516422366.SGD","LU0348767384.USD","LU0039217434.USD","LU0326950275.SGD","ONC","LU0856984785.SGD","LU0516423091.SGD","LU2328871848.SGD","LU1720050803.USD","IE00B0JY6N72.USD","688235"],"gpt_icon":0},{"id":"2533462501","title":"创新药概念持续调整 百济神州跌7.31% 机构指医药板块中最值得关注的仍是创新药赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2533462501","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533462501?lang=zh_cn&edition=full","pubTime":"2025-05-07 14:03","pubTimestamp":1746597782,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念持续调整，加科思 跌13.95%，百济神州跌7.31%，君实生物跌6.75%，荣昌生物跌6.6%，药明生物跌6.24%。国金证券研报指，医药板块中最值得关注的仍将是创新药赛道，该行认为对创新医药投资机会的把握将是贯穿2025年全年医药投资的主线，在当前时点重点看好创新药出海龙头和仿创结合龙头，同时积极关注会议数据发布和海外BD商务合作进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050714034194eedfd7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050714034194eedfd7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09939","BK1500","LU0307460666.USD","LU2328871848.SGD","BK1515","06978","06160","LU0588546209.SGD","LU1969619763.USD","BK1574","BK1588","BK1583"],"gpt_icon":0},{"id":"2533623745","title":"A股创新药概念午后持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌超5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533623745","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533623745?lang=zh_cn&edition=full","pubTime":"2025-05-07 13:56","pubTimestamp":1746597395,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["002294","688382","BK0196","BK0187","BK1161","LU2328871848.SGD","BK1588","159992","LU0588546209.SGD","ONC","159982","LU0307460666.USD","300723","09995","LU1064130708.USD","LU1969619763.USD","LU2148510915.USD","BK0183","06978","BK1583","688235","BK1574","399300","BK0188","06160","688192","BK1500","BK4139","LU1064131003.USD","BK0028","688331","BK0239"],"gpt_icon":0},{"id":"2533253366","title":"【创新药概念持续调整 百济神州跌近9%】午后创新药概念持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌逾5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533253366","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533253366?lang=zh_cn&edition=full","pubTime":"2025-05-07 13:54","pubTimestamp":1746597245,"startTime":"0","endTime":"0","summary":"午后创新药概念持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌逾5%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/07135450187475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1064131003.USD","BK1583","BK0196","BK0183","BK0187","06978","ONC","688235","300723","09995","BK1588","BK0239","LU2148510915.USD","LU1969619763.USD","BK0028","BK0188","BK1574","LU0588546209.SGD","688331","LU0307460666.USD","BK1500","LU1064130708.USD","LU2328871848.SGD","159992","002294","BK4139","688192","06160","BK1161","688382"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beigene.cn","stockEarnings":[{"period":"1week","weight":-0.1076},{"period":"1month","weight":0.1217},{"period":"3month","weight":0.0007},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.4462},{"period":"ytd","weight":0.2912}],"compareEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":0.1444},{"period":"3month","weight":0.0862},{"period":"6month","weight":0.0947},{"period":"1year","weight":0.228},{"period":"ytd","weight":0.1312}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"BeiGene Ltd是一家全球生物技术公司，致力于为全球癌症患者发现和开发肿瘤治疗方法。该公司已发现并开发三种批准药物，包括BRUKINSA，一种布鲁顿酪氨酸激酶的小分子抑制剂，用于治疗各种血癌；TEVIMBRA（tislelizumab），一种抗PD-1抗体免疫疗法，用于治疗各种实体瘤和血癌；以及是聚ADP核糖聚合酶1(PARP1)和PARP2的选择性小分子抑制剂pamiparib。该公司已获得在美国、中华人民共和国（中国）、欧盟、英国、加拿大、澳大利亚和其他国际市场销售BRUKINSA，在欧盟和中国销售替雷利珠单抗，以及在中国销售帕米帕尼的批准。它还专注于在Amgen Inc独家授权下在中国商业化癌症药物，如XGEVA、BLINCYTO、KYPROLIS等。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.009815},{"month":2,"riseRate":0.571429,"avgChangeRate":0.046604},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.052519},{"month":4,"riseRate":0.428571,"avgChangeRate":0.037509},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.061299},{"month":6,"riseRate":0.5,"avgChangeRate":0.011188},{"month":7,"riseRate":0.833333,"avgChangeRate":0.075403},{"month":8,"riseRate":0.833333,"avgChangeRate":0.065797},{"month":9,"riseRate":0.428571,"avgChangeRate":0.01247},{"month":10,"riseRate":0.571429,"avgChangeRate":-0.017395},{"month":11,"riseRate":0.571429,"avgChangeRate":0.120457},{"month":12,"riseRate":0.142857,"avgChangeRate":-0.068807}],"exchange":"SEHK","name":"百济神州","nameEN":"BEIGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.3","shortVersion":"4.33.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,06160,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}